A Study of the Safety and Effectiveness of Inhaled Mannitol for Adult Patients with Cystic Fibrosis

Overview

About this study

The purpose of this study is to provide evidence of the safety and effectiveness of inhaled mannitol for adult patients with cystic fibrosis.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Have given written informed consent to participate in this trial in accordance with local regulations
  • Have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 mEq/L) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype)
  • At least 18 years old
  • Have FEV1 > 40 % and < 90% predicted (using NHanes III [1])
  • Able to perform all the techniques necessary to measure lung function
  • Adherent with maintenance therapies (antibiotics and or rhDNase), if used, for at least 80% of the time in the two weeks prior to visit 1
  • If rhDNase and/or maintenance antibiotic are being used treatment must have been established at least 1 month prior to screening visit 0.
  • The subject should remain on the rhDNase and / or maintenance antibiotics for the duration of the trial.
  • The subject should not start treatment with rhDNase or maintenance antibiotics during this trial

Exclusion Criteria

  • Investigators, site personnel directly affiliated with this trial, or their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted
  • Considered "terminally ill" or eligible for lung transplantation
  • Have had a lung transplant
  • Used a maintenance nebulized hypertonic saline in the 2 weeks prior to visit 1
  • Have had a significant episode of hemoptysis (> 60 mL) in the three months prior to visit 0
  • Have had a myocardial infarction in the three months prior to visit 0
  • Have had a cerebral vascular accident in the three months prior to visit 0
  • Have had major ocular surgery in the three months prior to visit 0
  • Have had major abdominal, chest or brain surgery in the three months prior to visit 0
  • Have a known cerebral, aortic or abdominal aneurysm
  • Are breast feeding or pregnant, or plan to become pregnant while in the trial
  • Are using an unreliable form of contraception (female subjects at risk of pregnancy only)
  • Are participating in another investigative drug trial, parallel to, or within 4 weeks of screening visit 0
  • Have a known allergy to mannitol
  • Are using non-selective oral beta blockers
  • Have uncontrolled hypertension -i.e. systolic BP > 190 and / or diastolic BP > 100
  • Have a condition or in a situation which in the Investigator's opinion may put the subject at significant risk, may confound results or may interfere significantly with the subject's participation in the trial
  • Have a failed or incomplete MTT at trial entry

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Mark Wylam, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20201314

Mayo Clinic Footer